Pharmacogenetics of Antidepressant-Induced Disinhibition
Recruiting · NCT03953014 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →What this trial is about
The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Who can take part
Age range
6 Years to 17 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Aged 6 - 24 years
- Medical records available
- Diagnosis of MDD, anxiety disorder, or OCD
- Current or past history of SSRI therapy
Exclusion criteria
- Inability of parent/legal guardian to give informed consent
- Inability of the child to give informed assent
- Unwillingness of child to provide saliva sample for genetic analysis
- Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.
Where it is running
2 locations listed.
- Child and Adolescent Addiction, Mental Health & Psychiatry - Calgary, Alberta, Canada
- Child and Adolescent Addiction, Mental Health & Psychiatry - Calgary, Alberta, Canada